

Rafael G Dos Santos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8324482/publications.pdf>

Version: 2024-02-01

85
papers

3,945
citations

172443

29
h-index

138468

58
g-index

89
all docs

89
docs citations

89
times ranked

2168
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. <i>Psychological Medicine</i> , 2019, 49, 655-663.	4.5	479
2	Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 77-81.	1.4	364
3	Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. <i>Revista Brasileira De Psiquiatria</i> , 2015, 37, 13-20.	1.7	341
4	Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. <i>Therapeutic Advances in Psychopharmacology</i> , 2016, 6, 193-213.	2.7	204
5	Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. <i>Journal of Ethnopharmacology</i> , 2007, 112, 507-513.	4.1	166
6	Clinical validity and intrarater and test-retest reliability of the Structured Clinical Interview for DSM-5 Clinician Version (SCID-5/CV). <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 754-760.	1.8	145
7	Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 889-902.	3.1	134
8	Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. <i>Therapeutic Advances in Psychopharmacology</i> , 2017, 7, 141-157.	2.7	115
9	Autonomic, Neuroendocrine, and Immunological Effects of Ayahuasca. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 717-726.	1.4	109
10	Pharmacology of ayahuasca administered in two repeated doses. <i>Psychopharmacology</i> , 2012, 219, 1039-1053.	3.1	108
11	Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. <i>Revista Brasileira De Psiquiatria</i> , 2016, 38, 65-72.	1.7	98
12	The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging. <i>Journal of Psychopharmacology</i> , 2016, 30, 1230-1247.	4.0	85
13	Therapeutic use of serotonergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 108, 423-434.	6.1	82
14	Classical hallucinogens and neuroimaging: A systematic review of human studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 71, 715-728.	6.1	79
15	Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans. <i>Journal of Psychoactive Drugs</i> , 2016, 48, 195-205.	1.7	65
16	Safety and Side Effects of Ayahuasca in Humans—An Overview Focusing on Developmental Toxicology. <i>Journal of Psychoactive Drugs</i> , 2013, 45, 68-78.	1.7	64
17	Serotonergic psychedelics and personality: A systematic review of contemporary research. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 87, 118-132.	6.1	63
18	Phytocannabinoids and epilepsy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 135-143.	1.5	60

#	ARTICLE	IF	CITATIONS
19	Effects of ayahuasca on mental health and quality of life in naïve users: A longitudinal and cross-sectional study combination. <i>Scientific Reports</i> , 2020, 10, 4075.	3.3	58
20	Effects of the Natural β -Carboline Alkaloid Harmine, a Main Constituent of Ayahuasca, in Memory and in the Hippocampus: A Systematic Literature Review of Preclinical Studies. <i>Journal of Psychoactive Drugs</i> , 2017, 49, 1-10.	1.7	54
21	Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey. <i>Scientific Reports</i> , 2017, 7, 15201.	3.3	53
22	Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2021, 4, e2120603.	5.9	47
23	Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1264, 29-45.	1.6	47
24	Ayahuasca and Public Health: Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users. <i>Journal of Psychoactive Drugs</i> , 2019, 51, 135-145.	1.7	46
25	Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 517-526.	3.3	46
26	Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial. <i>Psychopharmacology</i> , 2021, 238, 453-459.	3.1	43
27	Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 540-550.	1.4	42
28	Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 121-133.	3.2	41
29	A Critical Evaluation of Reports Associating Ayahuasca with Life-Threatening Adverse Reactions. <i>Journal of Psychoactive Drugs</i> , 2013, 45, 179-188.	1.7	38
30	The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 901-910.	2.5	31
31	Hallucinogenic/psychedelic 5HT _{2A} receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. <i>Journal of Psychopharmacology</i> , 2021, 35, 453-458.	4.0	30
32	Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): transcultural adaptation of the Brazilian version. <i>Revista De Psiquiatria Clinica</i> , 2017, 44, 10-19.	0.6	28
33	Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature. <i>Therapeutic Advances in Psychopharmacology</i> , 2019, 9, 204512531984577.	2.7	25
34	Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 267-274.	1.4	25
35	Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 687546.	2.6	25
36	Risk assessment of ayahuasca use in a religious context: self-reported risk factors and adverse effects. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 362-369.	1.7	24

#	ARTICLE	IF	CITATIONS
37	Ayahuasca, an ancient substance with traditional and contemporary use in neuropsychiatry and neuroscience. <i>Epilepsy and Behavior</i> , 2019, 121, 106300.	1.7	22
38	Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 658-669.	2.9	22
39	The antiaddictive effects of ibogaine: A systematic literature review of human studies. <i>Journal of Psychedelic Studies</i> , 2017, 1, 20-28.	1.2	21
40	Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up. <i>Revista De Psiquiatria Clinica</i> , 2018, 45, 22-24.	0.6	21
41	Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016–2020) systematic review of preclinical and human studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 541-556.	3.2	21
42	Immunological Effects of Ayahuasca in Humans. <i>Journal of Psychoactive Drugs</i> , 2014, 46, 383-388.	1.7	20
43	The adverse events of ibogaine in humans: an updated systematic review of the literature (2015–2020). <i>Psychopharmacology</i> , 2022, 239, 1977-1987.	3.1	18
44	Assessment of the Psychotherapeutic Effects of Ritual Ayahuasca Use on Drug Dependency: A Pilot Study. , 2014, , 183-196.		18
45	Stability Evaluation of DMT and Harmala Alkaloids in Ayahuasca Tea Samples. <i>Molecules</i> , 2020, 25, 2072.	3.8	16
46	Quality of Life, Mental Health, Personality and Patterns of Use in Self-Medicated Cannabis Users with Chronic Diseases: A 12-Month Longitudinal Study. <i>Phytotherapy Research</i> , 2020, 34, 1670-1677.	5.8	16
47	Modulation of the Endocannabinoid and Oxytocinergic Systems as a Potential Treatment Approach for Social Anxiety Disorder. <i>CNS Drugs</i> , 2019, 33, 1031-1038.	5.9	14
48	Acute Psychological Adverse Reactions in First-Time Ritual Ayahuasca Users. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 163-171.	1.4	14
49	Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 761-776.	2.4	13
50	Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer. <i>BMC Psychiatry</i> , 2019, 19, 321.	2.6	11
51	Personality Inventory for DSM-5 (PID-5): cross-cultural adaptation and content validity in the Brazilian context. <i>Trends in Psychiatry and Psychotherapy</i> , 2019, 41, 297-300.	0.8	11
52	Toxicity of chronic ayahuasca administration to the pregnant rat: how relevant it is regarding the human, ritual use of ayahuasca?. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2010, 89, 533-535.	1.4	10
53	Detoxification from methadone using low, repeated, and increasing doses of ibogaine: A case report. <i>Journal of Psychedelic Studies</i> , 2017, 1, 29-34.	1.2	10
54	Polypharmacology or ‘Pharmacological Promiscuity’ In Psychedelic Research: What Are We Missing?. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3191-3193.	3.5	10

#	ARTICLE	IF	CITATIONS
55	Effects of Ayahuasca on Personality: Results of Two Randomized, Placebo-Controlled Trials in Healthy Volunteers. <i>Frontiers in Psychiatry</i> , 2021, 12, 688439.	2.6	10
56	An analytical study of iboga alkaloids contained in Tabernanthe iboga-derived products offered by ibogaine treatment providers. <i>Revista De Psiquiatria Clinica</i> , 2020, 47, 51-54.	0.6	10
57	Ayahuasca e redu�o do uso abusivo de psicoativos: efic�cia terap�utica?. <i>Psicologia: Teoria E Pesquisa</i> , 2006, 22, 363-370.	0.1	9
58	The effects of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC) on the recognition of emotions in facial expressions: A systematic review of randomized controlled trials. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 118, 236-246.	6.1	9
59	Ayahuasca: what mental health professionals need to know. <i>Revista De Psiquiatria Clinica</i> , 2017, 44, 103-109.	0.6	8
60	Possible Interactions Between 5-HT2A Receptors and the Endocannabinoid System in Humans. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 644-646.	1.4	8
61	Psychedelics and Personality. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2304-2306.	3.5	8
62	Salvinorin A and Related Compounds as Therapeutic Drugs for Psychostimulant-Related Disorders. <i>Current Drug Abuse Reviews</i> , 2015, 7, 128-132.	3.4	8
63	Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof-of-concept, randomized, placebo-controlled trials. <i>Human Psychopharmacology</i> , 2022, , e2834.	1.5	8
64	Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 789-801.	2.4	8
65	Ayahuasca Alters Structural Parameters of the Rat Aorta. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 66, 58-62.	1.9	7
66	Essential oil-based dispersive liquid-liquid microextraction for the determination of N,N-dimethyltryptamine and �-carbolines in human plasma: A novel solvent-free alternative. <i>Talanta</i> , 2021, 225, 121976.	5.5	7
67	Ayahuasca and Public Health II: Health Status in a Large Sample of Ayahuasca-Ceremony Participants in the Netherlands. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 247-258.	1.7	7
68	��Ayahuasca turned on my mind��s eye�� Enhanced visual imagery after ayahuasca intake in a man with ��blind imagination�� (aphantasia). <i>Journal of Psychedelic Studies</i> , 2018, 2, 74-77.	1.2	6
69	The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2023, 273, 129-155.	3.2	6
70	Anxiety, panic, and hopelessness during and after ritual ayahuasca intake in a woman with generalized anxiety disorder: A case report. <i>Journal of Psychedelic Studies</i> , 2017, 1, 35-39.	1.2	5
71	Hallucinogens/psychedelics resurrected as new tools in psychiatric therapy. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 119-120.	1.7	5
72	Adverse Effects After Ayahuasca Administration in the Clinical Setting. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 321-324.	1.4	5

#	ARTICLE	IF	CITATIONS
73	Potential Therapeutic Effects of Psilocybin/Psilocin are Minimized While Possible Adverse Reactions are Overrated. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 131-132.	2.0	4
74	Translational evidence for ayahuasca as an antidepressant: what's next?. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 275-276.	1.7	4
75	Cannabidiol for the Treatment of Drug Use Disorders. , 2017, , 939-946.		3
76	O uso do canabidiol (CBD) no tratamento da doença de Parkinson e suas comorbidades. , 2019, 98, 46-51.	0.1	3
77	Psychedelic Medicines in Major Depression: Progress and Future Challenges. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1305, 515-533.	1.6	3
78	Cross-cultural adaptation of the City Birth Trauma Scale for the Brazilian context. <i>Revista De Psiquiatria Clinica</i> , 2020, 47, 110-118.	0.6	2
79	Letter to the Editor. <i>Journal of Clinical Forensic and Legal Medicine</i> , 2016, 38, 116-117.	1.0	1
80	Intoxicação por ayahuasca. <i>Medicina Clínica</i> , 2017, 149, 461-462.	0.6	1
81	Cannabidiol for the Treatment of Epilepsy: An Overview of Possible Mechanisms of Action and Preclinical and Human Studies. , 2017, , 795-801.		1
82	Psychedelics, Glutamate, and Neuroimaging Studies. <i>Anesthesiology</i> , 2014, 120, 1521-1522.	2.5	1
83	Unveiling ayahuasca psychopharmacology: the accomplishments of Jordi Riba (1968-2020). <i>Revista Brasileira De Psiquiatria</i> , 2020, , .	1.7	1
84	Ayahuasca intoxication. <i>Medicina Clínica (English Edition)</i> , 2017, 149, 461-462.	0.2	0
85	Classical hallucinogens as antidepressant drugs: A cautionary approach. <i>Current Neuropharmacology</i> , 2022, 20, .	2.9	0